AbbVie Inc. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax
AbbVie Inc. (ABBV) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax of $63.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax · last filed 2026-08-03
- AbbVie Inc. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2026-06-30 was $63.00M.
- AbbVie Inc. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2026-03-31 was $40.00M.
- AbbVie Inc. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2025-12-31 was $23.00M, a 78.30% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2025-09-30 was -$1.00M.
- AbbVie Inc. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2025 was -$150.00M, a 287.50% decline from fiscal 2024.
- AbbVie Inc. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2024 was $80.00M.
- AbbVie Inc. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2023 was -$84.00M.
- AbbVie Inc. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $63.00M 10-Q · filed 2026-08-03 | $103.00M 10-Q · filed 2026-08-03 | $126.00M derived: sum of 3 quarters · filed 2026-08-03 | $125.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $40.00M 10-Q · filed 2026-05-08 | $63.00M derived: sum of 2 quarters · filed 2026-05-08 | $62.00M derived: sum of 3 quarters · filed 2026-05-08 | -$91.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $23.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $22.00M derived: sum of 2 quarters · filed 2026-02-20 | -$131.00M derived: sum of 3 quarters · filed 2026-08-03 | -$150.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | -$1.00M 10-Q · filed 2025-11-04 | -$154.00M derived: sum of 2 quarters · filed 2026-08-03 | -$173.00M 10-Q · filed 2025-11-04 | -$67.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$153.00M 10-Q · filed 2026-08-03 | -$172.00M 10-Q · filed 2026-08-03 | -$66.00M derived: sum of 3 quarters · filed 2026-08-03 | -$128.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$19.00M 10-Q · filed 2026-05-08 | $87.00M derived: sum of 2 quarters · filed 2026-05-08 | $25.00M derived: sum of 3 quarters · filed 2026-05-08 | $31.00M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $106.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $44.00M derived: sum of 2 quarters · filed 2026-02-20 | $50.00M derived: sum of 3 quarters · filed 2026-02-20 | $80.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | -$62.00M 10-Q · filed 2025-11-04 | -$56.00M derived: sum of 2 quarters · filed 2025-11-04 | -$26.00M 10-Q · filed 2025-11-04 | -$108.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $6.00M 10-Q · filed 2025-08-04 | $36.00M 10-Q · filed 2025-08-04 | -$46.00M derived: sum of 3 quarters · filed 2026-02-20 | $6.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $30.00M 10-Q · filed 2025-05-09 | -$52.00M derived: sum of 2 quarters · filed 2026-02-20 | $0.00 derived: sum of 3 quarters · filed 2026-02-20 | -$13.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | -$82.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$30.00M derived: sum of 2 quarters · filed 2026-02-20 | -$43.00M derived: sum of 3 quarters · filed 2026-02-20 | -$84.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | $52.00M 10-Q · filed 2024-11-04 | $39.00M derived: sum of 2 quarters · filed 2024-11-04 | -$2.00M 10-Q · filed 2024-11-04 | -$100.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | -$13.00M 10-Q · filed 2024-08-07 | -$54.00M 10-Q · filed 2024-08-07 | -$152.00M derived: sum of 3 quarters · filed 2025-02-14 | -$69.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | -$41.00M 10-Q · filed 2024-05-03 | -$139.00M derived: sum of 2 quarters · filed 2025-02-14 | -$56.00M derived: sum of 3 quarters · filed 2025-02-14 | -$29.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | -$98.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | -$15.00M derived: sum of 2 quarters · filed 2025-02-14 | $12.00M derived: sum of 3 quarters · filed 2025-02-14 | $0.00 10-K · filed 2025-02-14 |
| 2022-09-30 | $83.00M 10-Q · filed 2023-11-06 | $110.00M derived: sum of 2 quarters · filed 2023-11-06 | $98.00M 10-Q · filed 2023-11-06 | $134.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $27.00M 10-Q · filed 2023-08-07 | $15.00M 10-Q · filed 2023-08-07 | $51.00M derived: sum of 3 quarters · filed 2024-02-20 | $108.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$12.00M 10-Q · filed 2023-05-05 | $24.00M derived: sum of 2 quarters · filed 2024-02-20 | $81.00M derived: sum of 3 quarters · filed 2024-02-20 | $93.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $93.00M derived: sum of 2 quarters · filed 2024-02-20 | $105.00M derived: sum of 3 quarters · filed 2024-02-20 | $151.00M 10-K · filed 2024-02-20 |
| 2021-09-30 | $57.00M 10-Q · filed 2022-11-04 | $69.00M derived: sum of 2 quarters · filed 2022-11-04 | $115.00M 10-Q · filed 2022-11-04 | $52.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $12.00M 10-Q · filed 2022-08-04 | $58.00M 10-Q · filed 2022-08-04 | -$5.00M derived: sum of 3 quarters · filed 2023-02-17 | -$62.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $46.00M 10-Q · filed 2022-05-06 | -$17.00M derived: sum of 2 quarters · filed 2023-02-17 | -$74.00M derived: sum of 3 quarters · filed 2023-02-17 | |
| 2020-12-31 | -$63.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$120.00M derived: sum of 2 quarters · filed 2023-02-17 | -$131.00M 10-K · filed 2023-02-17 | |
| 2020-09-30 | -$57.00M 10-Q · filed 2021-11-02 | -$68.00M 10-Q · filed 2021-11-02 | ||
| 2019-12-31 | $141.00M 10-K · filed 2022-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |